Therapeutic Programs

Aileron has built a broad and growing drug candidate pipeline across a host of therapeutic areas and is currently advancing multiple Stapled Peptide programs through preclinical development. Aileron's Stapled Peptides have demonstrated their unique ability to penetrate cells throughout the body and modulate intracellular and extracellular protein-protein interactions, critical control points for most human diseases. The ability to target and regulate these control points affords the unique opportunity to exploit potentially thousands of well characterized, yet currently "undruggable" cellular targets with applications in all human diseases.

Internally and through its collaboration with Roche, Aileron is initially focusing on candidates targeting cancer, infectious disease, metabolic disease and immune/inflammatory diseases. To review published data supporting Aileron's therapeutic programs, please visit our scientific publications page.